Withdrawal of non-binding proposal

In the Company’s announcement of the conclusion of its strategic review released on 18 August, 2015, reference was made to a non-binding preliminary proposal of US$110 million for the Company’s Point-of-Care business. That proposal has now been withdrawn.

The proposals referenced in the Company’s announcements released on 24 August, 2015 are not affected.

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

New data using EKF PointMan™

EKF Diagnostics announces the latest results from its collaboration with the Institute of Life Sciences at the University of Swansea.

Contract win and regulatory approval

EKF Diagnostics announces that it has signed a new distribution contract in China and that one of its OEM partners has received further regulatory approval across several target territories.

Stanbio Life Sciences re-branded

Stanbio Life Sciences re-branded as EKF Life Sciences.

EKF collaborator to deliver Kelly West Lecture at ADA

Dr. Andrzej Krolewski recognized for significant contribution to diabetes epidemiology .

EKF Molecular Diagnostics and GILUPI announce CTC DNA enrichment success

EKF Molecular Diagnostics and GILUPI announces results from collaborative work using GILUPI CellCollectorTM and PointManTM DNA enrichment technology.